Jazz Pharmaceuticals (JAZZ) announced the U.S. FDA has accepted the supplemental New Drug Application for Zepzelca in combination with Atezolizumab as a first-line maintenance treatment for people with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin, and etoposide for Priority Review, with a Prescription Drug User Fee Act action date of October 7, 2025.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals presents late-breaking phase 4 data showcasing Xywav
- Jazz Pharmaceuticals: Promising Developments and Positive Data Reinforce Buy Rating
- Jazz Pharmaceuticals announces ‘positive’ results from Phase 3 IMforte study
- Jazz Pharmaceuticals reports 15.2 months median PFS in Phase 2 trial
- Insiders Pour Millions into These 3 Stocks — Here’s Why They Draw Plaudits Across the Board